Unfortunately, a phase III clinical trial using bevacizumab, a humanized antibody against VEGF approved for the treatment of colon cancer, reported minimal overall survival benefit for PDAC patients with advanced disease [45] underscoring the need to identify non-VEGF pathways important for PDAC angiogenesis. The gene discussed is VEGFA; the disease is colonic neoplasm.